BTK Inhibitors and Chemoimmunotherapy for CLL

Philip Thompson

doi:10.1016/S2152-2650(20)30449-3

BTK Inhibitors and Chemoimmunotherapy for CLL

Philip Thompson

Leukemia

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	S22-S24
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
DOIs	https://doi.org/10.1016/S2152-2650(20)30449-3
State	Published - Sep 2020

Keywords

CLL
chemoimmunotherapy
iFCG
iFCR
ibrutinib

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S2152-2650(20)30449-3

Cite this

@article{3613d8e0c5954d45948c931badb2005c,

title = "BTK Inhibitors and Chemoimmunotherapy for CLL",

keywords = "CLL, chemoimmunotherapy, iFCG, iFCR, ibrutinib",

author = "Philip Thompson",

year = "2020",

month = sep,

doi = "10.1016/S2152-2650(20)30449-3",

language = "English (US)",

volume = "20",

pages = "S22--S24",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - BTK Inhibitors and Chemoimmunotherapy for CLL

AU - Thompson, Philip

PY - 2020/9

Y1 - 2020/9

KW - CLL

KW - chemoimmunotherapy

KW - iFCG

KW - iFCR

KW - ibrutinib

UR - http://www.scopus.com/inward/record.url?scp=85089821036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089821036&partnerID=8YFLogxK

U2 - 10.1016/S2152-2650(20)30449-3

DO - 10.1016/S2152-2650(20)30449-3

M3 - Article

C2 - 32862855

AN - SCOPUS:85089821036

SN - 2152-2650

VL - 20

SP - S22-S24

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

BTK Inhibitors and Chemoimmunotherapy for CLL

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this